VANDA PHARMACEUTICALS INC. Increase (Decrease) in Restricted Cash
VANDA PHARMACEUTICALS INC. (VNDA) reported Increase (Decrease) in Restricted Cash of $46.00 thousand for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-17.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInRestrictedCash · last filed 2017-02-17
- VANDA PHARMACEUTICALS INC. increase (decrease) in restricted cash for the quarter ending 2014-12-31 was $0.00.
- VANDA PHARMACEUTICALS INC. increase (decrease) in restricted cash for the quarter ending 2014-09-30 was $0.00.
- VANDA PHARMACEUTICALS INC. increase (decrease) in restricted cash for the quarter ending 2014-06-30 was -$100.00K.
- VANDA PHARMACEUTICALS INC. increase (decrease) in restricted cash for the quarter ending 2014-03-31 was -$145.00K.
- VANDA PHARMACEUTICALS INC. increase (decrease) in restricted cash for fiscal 2016 was $46.00K.
- VANDA PHARMACEUTICALS INC. increase (decrease) in restricted cash for fiscal 2014 was -$245.00K.
- VANDA PHARMACEUTICALS INC. increase (decrease) in restricted cash for fiscal 2011 was $600.00K.
| Period end | Increase (Decrease) in Restricted Cash 3 month | Increase (Decrease) in Restricted Cash 6 month | Increase (Decrease) in Restricted Cash 9 month | Increase (Decrease) in Restricted Cash 12 month |
|---|---|---|---|---|
| 2016-12-31 | $46.00K 10-K · filed 2017-02-17 | |||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $0.00 derived: sum of 2 quarters · filed 2017-02-17 | -$100.00K derived: sum of 3 quarters · filed 2017-02-17 | -$245.00K 10-K · filed 2017-02-17 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | -$100.00K derived: sum of 2 quarters · filed 2015-11-04 | -$245.00K 10-Q · filed 2015-11-04 | |
| 2014-06-30 | -$100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-31 | -$245.00K 10-Q · filed 2015-07-31 | ||
| 2014-03-31 | -$145.00K 10-Q · filed 2015-05-07 | |||
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $500.00K derived: sum of 2 quarters · filed 2014-02-25 | $600.00K 10-K · filed 2014-02-25 | |
| 2011-09-30 | $500.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | $600.00K 10-Q · filed 2012-11-08 | ||
| 2011-06-30 | $100.00K 10-Q · filed 2012-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |